Mouse models of glioblastoma for the evaluation of novel therapeutic strategies
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Glioblastoma (GBM) is an incurable brain tumor with a median survival of approximately 15 months despite an aggressive standard of care that includes surgery, chemotherapy, and ionizing radiation. Mouse models have advanced our understanding of GBM biology and the development of novel therapeutic strategies for GBM patients. However, model selection is crucial when testing developmental therapeutics, and each mouse model of GBM has unique advantages and disadvantages that can influence the validity and translatability of experimental results. To shed light on this process, we discuss the strengths and limitations of 3 types of mouse GBM models in this review: syngeneic models, genetically engineered mouse models, and xenograft models, including traditional xenograft cell lines and patient-derived xenograft models.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Samstein, R. M., Lee, C.-H., Shoushtari, A. N., Hellmann, M. D., Shen, R., Janjigian, Y. Y., Barron, D. A., Zehir, A., Jordan, E. J., Omuro, A., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0312-8 · Cited by 4,071 · cited 1×
“Moreover, human GBM cells have a relatively low mutational burden compared to other aggressive malignancies(17), which may limit the efficacy of immunotherapy.(18) In contrast, many of the syngeneic murine GBM models carry high mutational burdens frequently hundreds of folds higher than human GBM.”
BackgroundSelf-citationGao, H., Korn, J. M., Ferretti, S., Monahan, J. E., Wang, Y., Singh, M., Zhang, C., Schnell, C., Yang, G., Zhang, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3954 · Cited by 1,393
Exciting New Advances in Neuro-Oncology: The Avenue to a Cure for Malignant Glioma
Van Meir, E. G., Hadjipanayis, C. G., Norden, A. D., Shu, H. K., Wen, P. Y., & Olson, J. J. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20069 · Cited by 1,372
Patient-derived tumour xenografts as models for oncology drug development
Tentler, J. J., Tan, A. C., Weekes, C. D., Jimeno, A., Leong, S., Pitts, T. M., Arcaroli, J. J., Messersmith, W. A., & Eckhardt, S. G. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.61 · Cited by 1,277
Pollard, S. M., Yoshikawa, K., Clarke, I. D., Danovi, D., Stricker, S., Russell, R., Bayani, J., Head, R., Lee, M., Bernstein, M., et al. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.03.014 · Cited by 1,025 · cited 1×
“This can be avoided by maintaining cells in serum-free neural stem cell media, allowing for the maintenance of a human GBM phenotype.(92) Unfortunately, recent reports detailing differences in the DNA profile of widely distributed “classic” human glioblastoma cell lines and the original cells(93), have increased”
BackgroundOrigin of the U87MG glioma cell line: Good news and bad news
Allen, M., Bjerke, M., Edlund, H., Nelander, S., & Westermark, B. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf6853 · Cited by 466 · cited 1×
“challenged when the lab that initially isolated the U87 cell line found that U87 cell line widely available from ATCC had a different DNA profile from that of the original cells.(93) Subsequent analysis revealed that the U87 line from ATCC was of CNS origin and likely a GBM line, though of unclear origin.”
ResultThe p53 Pathway in Glioblastoma
Zhang, Y., Dube, C., Gibert, M., Cruickshanks, N., Wang, B., Coughlan, M., Yang, Y., Setiady, I., Deveau, C., Saoud, K., et al. (2018) · Cancers · doi:10.3390/cancers10090297 · Cited by 440
Glioblastoma Model Using Human Cerebral Organoids
Ogawa, J., Pao, G. M., Shokhirev, M. N., & Verma, I. M. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.105 · Cited by 391
Cited by
TREM2 inhibition triggers antitumor cell activity of myeloid cells in glioblastoma
Sun, R., Han, R., McCornack, C., Khan, S., Tabor, G. T., Chen, Y., Hou, J., Jiang, H., Schoch, K. M., Mao, D. D., et al. (2023) · Science Advances · doi:10.1126/sciadv.ade3559 · Cited by 119
Glioblastoma modeling with 3D organoids: progress and challenges
Wang, X., Sun, Y., Zhang, D. Y., Ming, G.-L., & Song, H. (2023) · Oxford Open Neuroscience · doi:10.1093/oons/kvad008 · Cited by 46
“Manipulation of key genetic drivers have led to glioma formation in mouse models, such as combined mutations of NF1/PTEN/TP53, KRAS G12D /AKT or EGFRvIII/Ink4a/PTEN [5, 68– 81].”
BackgroundMethodRadiosensitizers in Cancer Therapy: A Global Bibliometric Analysis
Annagiri, S., Harary, P. M., Hori, Y. S., Lam, F. C., AbuReesh, D., Tayag, A., Ustrzynski, L., Emrich, S. C., Chang, S. D., & Park, D. J. (2025) · doi:10.1101/2025.06.26.661878 · Cited by 3
Metadata
- Authors
- Haddad, A. F., Young, J. S., Amara, D., Berger, M. S., Raleigh, D. R., Aghi, M. K., & Butowski, N. A.
- Venue
- Neuro-Oncology Advances
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-01-01
- Volume
- 3
- Issue
- 1
- Pages
- vdab100-vdab100
- ISSN
- 2632-2498 (ISSN-L)
- OpenAlex
- W3184278920
- Cited by
- 203
- References
- 12
- FWCI
- 13.70
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mouse models of glioblastoma for the evaluation of novel therapeutic strategies. https://app.cochat.ai/papers/10.1093/noajnl/vdab100
- The paper
- Haddad, A. F., Young, J. S., Amara, D., Berger, M. S., Raleigh, D. R., Aghi, M. K., & Butowski, N. A. (2021). Mouse models of glioblastoma for the evaluation of novel therapeutic strategies. Neuro-Oncology Advances. https://doi.org/10.1093/noajnl/vdab100
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.